HK1209761A1 - 多肽 - Google Patents

多肽

Info

Publication number
HK1209761A1
HK1209761A1 HK15110388.2A HK15110388A HK1209761A1 HK 1209761 A1 HK1209761 A1 HK 1209761A1 HK 15110388 A HK15110388 A HK 15110388A HK 1209761 A1 HK1209761 A1 HK 1209761A1
Authority
HK
Hong Kong
Prior art keywords
polypeptides
Prior art date
Application number
HK15110388.2A
Other languages
English (en)
Inventor
Lars Abrahmsn
Caroline Ekblad
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of HK1209761A1 publication Critical patent/HK1209761A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HK15110388.2A 2010-07-09 2013-08-23 多肽 HK1209761A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39928510P 2010-07-09 2010-07-09
US40356110P 2010-09-17 2010-09-17

Publications (1)

Publication Number Publication Date
HK1209761A1 true HK1209761A1 (zh) 2016-04-08

Family

ID=44630120

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15110388.2A HK1209761A1 (zh) 2010-07-09 2013-08-23 多肽
HK13109912.1A HK1182719A1 (zh) 2010-07-09 2013-08-23 多肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK13109912.1A HK1182719A1 (zh) 2010-07-09 2013-08-23 多肽

Country Status (22)

Country Link
US (3) US9211344B2 (zh)
EP (2) EP2590993B1 (zh)
JP (2) JP5827994B2 (zh)
KR (1) KR101884654B1 (zh)
CN (3) CN110437321A (zh)
AU (1) AU2011275766B2 (zh)
BR (1) BR112013000452A2 (zh)
CA (1) CA2804002C (zh)
DK (2) DK2933262T3 (zh)
ES (2) ES2676403T3 (zh)
HK (2) HK1209761A1 (zh)
IL (1) IL223989B (zh)
LT (1) LT2933262T (zh)
MX (1) MX2013000314A (zh)
MY (1) MY161679A (zh)
NO (1) NO2933262T3 (zh)
NZ (1) NZ604805A (zh)
PL (2) PL2933262T3 (zh)
RU (1) RU2577964C2 (zh)
TR (1) TR201809437T4 (zh)
WO (1) WO2012004384A2 (zh)
ZA (1) ZA201300994B (zh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
KR101884654B1 (ko) 2010-07-09 2018-08-02 애피바디 에이비 폴리펩타이드
ES2641869T3 (es) 2010-09-28 2017-11-14 Aegerion Pharmaceuticals, Inc. Polipéptidos de fusión de leptina-ABD con duración de acción aumentada
KR102030531B1 (ko) 2011-05-21 2019-10-10 마크로제닉스, 인크. 탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도
EP2729481B1 (en) 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
CN103957926B (zh) * 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
MY167232A (en) 2012-02-20 2018-08-14 Swedish Orphan Biovitrum Ab Publ Polypeptides binding to human complement c5
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
WO2013143890A1 (en) 2012-03-28 2013-10-03 Affibody Ab Oral administration
US10155792B2 (en) 2012-09-25 2018-12-18 Affibody Ab Albumin binding polypeptide
EP2904013B1 (en) 2012-10-05 2018-11-07 Affibody AB Her3 binding polypeptides
WO2014064237A1 (en) 2012-10-25 2014-05-01 Affibody Ab Abd binding polypeptide
PL2912051T3 (pl) 2012-10-25 2018-08-31 Affibody Ab Sposób rozdzielania białek zawierających domenę wiążącą albuminę
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
WO2014076177A1 (en) * 2012-11-14 2014-05-22 Affibody Ab New polypeptide
WO2014096163A1 (en) * 2012-12-19 2014-06-26 Affibody Ab New polypeptides
CN105246503A (zh) 2013-03-14 2016-01-13 第一三共株式会社 Pcsk9的新颖结合蛋白
WO2014140366A1 (en) * 2013-03-15 2014-09-18 Affibody Ab New polypeptides
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US9994626B2 (en) 2013-08-28 2018-06-12 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement C5
CN105473606A (zh) 2013-08-28 2016-04-06 阿菲博迪公司 具有突变的支架的结合多肽
EP3038642A4 (en) 2013-08-30 2017-01-18 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP6660297B2 (ja) 2013-11-11 2020-03-11 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を処置するためのインターロイキン−１０の使用方法
EP3083675B1 (en) 2013-12-20 2018-03-07 Affibody AB Engineered albumin binding polypeptide
US10774119B2 (en) 2014-05-22 2020-09-15 Pieris Pharmaceuticals Gmbh Specific-binding polypeptides and uses thereof
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CN107108721B (zh) 2014-09-29 2021-09-07 杜克大学 包含hiv-1包膜靶向臂的双特异性分子
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
JP6675394B2 (ja) 2014-10-22 2020-04-01 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害の治療のためにインターロイキン−１０を使用する方法
RU2749712C2 (ru) 2015-01-12 2021-06-16 Аффибоди Аб IL-17A-связывающие полипептиды
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
IL276944B (en) * 2015-04-02 2022-07-01 Molecular Partners Ag Designed regions containing ankyrin repeats with specific binding to serum albumin
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
EP3341012A4 (en) 2015-08-25 2019-03-20 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
WO2019032827A1 (en) 2017-08-09 2019-02-14 Massachusetts Institute Of Technology PEPTIDE ALBUMIN BINDING CONJUGATES AND METHODS THEREOF
CN108362873B (zh) * 2018-02-13 2021-06-01 苏州仁端生物医药科技有限公司 一种镉离子检测试剂盒及其应用
WO2019175176A1 (en) 2018-03-13 2019-09-19 Affibody Ab Polypeptides based on a novel scaffold
WO2021043757A1 (en) 2019-09-02 2021-03-11 Biotest Ag Factor viii protein with increased half-life
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
WO2021089695A1 (en) 2019-11-05 2021-05-14 Affibody Ab Polypeptides
CN114929261A (zh) 2020-02-17 2022-08-19 生物测试股份公司 凝血因子viii的皮下施用
EP3878515A1 (en) 2020-03-09 2021-09-15 Hober Biotech AB Therapeutic agent targeting her2
US20240101605A1 (en) 2020-12-21 2024-03-28 Affibody Ab New polypeptide
JP2024506070A (ja) 2021-02-15 2024-02-08 アフィボディ アクティエボラーグ 新規ｈｅｒ２結合ポリペプチド
CN113416683B (zh) * 2021-06-01 2023-05-02 南昌大学 一种大肠杆菌Nissle 1917基因工程菌及其制备方法和应用
WO2023152144A1 (en) 2022-02-08 2023-08-17 Affibody Ab Protein z variants binding thymic stromal lymphopoietin and their medical use

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6362225B1 (en) 1999-01-21 2002-03-26 George Andreakos Target therapies for treating common viral infections
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
ATE337403T1 (de) 1999-12-24 2006-09-15 Genentech Inc Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
US7288265B1 (en) 2000-10-16 2007-10-30 Lectec Corporation Treating viral infection at smallpox vaccination site
EP1353937A4 (en) * 2000-12-29 2005-04-13 Savient Pharmaceuticals Inc SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
DE05733048T1 (de) * 2004-04-06 2007-05-10 Affibody Ab Serumalbuminbindende peptidkonjugate zur arzneimittelherstellung
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
CN101128487B (zh) * 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
BRPI0711796A2 (pt) * 2006-05-24 2011-12-06 Bayer Schering Pharma Aktiendesellschaft anticorpos de bloqueio de função de integrinas anti-alfa5beta1 humanos e humanizados com imunogenicidade reduzida
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
CN101646689A (zh) * 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
AU2007306340A1 (en) * 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and use thereof
DE08786222T1 (de) * 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
CN102037121B (zh) 2008-03-26 2013-07-10 奥拉姆德有限公司 用于口服给予蛋白质的方法和组合物
CN101294178A (zh) 2008-05-26 2008-10-29 江南大学 一种用两阶段培养法提高发酵生产透明质酸产量的方法
CN101294187B (zh) * 2008-06-06 2013-07-31 暨南大学 一种缓释生物活性多肽的方法与应用
CN102123697B (zh) 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
KR101884654B1 (ko) 2010-07-09 2018-08-02 애피바디 에이비 폴리펩타이드
US20120027058A1 (en) 2010-07-29 2012-02-02 The Regents Of The University Of Michigan Portable, wireless multi-channel impedance analyzer
ES2641869T3 (es) 2010-09-28 2017-11-14 Aegerion Pharmaceuticals, Inc. Polipéptidos de fusión de leptina-ABD con duración de acción aumentada
CN103347532A (zh) 2011-02-04 2013-10-09 爱奇司治疗公司 口服可生物利用肽药物组合物及其方法
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
WO2013143890A1 (en) 2012-03-28 2013-10-03 Affibody Ab Oral administration
US10155792B2 (en) 2012-09-25 2018-12-18 Affibody Ab Albumin binding polypeptide
EP3083675B1 (en) 2013-12-20 2018-03-07 Affibody AB Engineered albumin binding polypeptide

Also Published As

Publication number Publication date
EP2590993A2 (en) 2013-05-15
RU2013102953A (ru) 2014-08-20
NO2933262T3 (zh) 2018-09-29
PL2590993T3 (pl) 2015-10-30
CN110437320A (zh) 2019-11-12
CA2804002A1 (en) 2012-01-12
EP2933262B1 (en) 2018-05-02
NZ604805A (en) 2014-09-26
TR201809437T4 (tr) 2018-07-23
ZA201300994B (en) 2020-05-27
IL223989B (en) 2018-10-31
KR101884654B1 (ko) 2018-08-02
EP2933262A1 (en) 2015-10-21
DK2933262T3 (en) 2018-06-25
AU2011275766A1 (en) 2013-01-10
RU2577964C2 (ru) 2016-03-20
JP2016053047A (ja) 2016-04-14
CN110437321A (zh) 2019-11-12
ES2676403T3 (es) 2018-07-19
US10329331B2 (en) 2019-06-25
JP6486810B2 (ja) 2019-03-20
MX2013000314A (es) 2013-01-29
US20160108095A1 (en) 2016-04-21
JP2013534421A (ja) 2013-09-05
HK1182719A1 (zh) 2013-12-06
CN103003296A (zh) 2013-03-27
US9211344B2 (en) 2015-12-15
DK2590993T3 (en) 2015-06-29
PL2933262T3 (pl) 2018-10-31
BR112013000452A2 (pt) 2020-02-11
CA2804002C (en) 2021-07-20
AU2011275766B2 (en) 2015-10-22
US20140162956A1 (en) 2014-06-12
LT2933262T (lt) 2018-07-10
EP2590993B1 (en) 2015-05-06
WO2012004384A2 (en) 2012-01-12
ES2540114T3 (es) 2015-07-08
KR20130034043A (ko) 2013-04-04
US20190375799A1 (en) 2019-12-12
MY161679A (en) 2017-05-15
JP5827994B2 (ja) 2015-12-02
WO2012004384A3 (en) 2012-03-29
CN110437320B (zh) 2023-10-20

Similar Documents

Publication Publication Date Title
HRP20191852T8 (hr) Polipeptidi
HK1182719A1 (zh) 多肽
DK3342786T3 (en) Anti-dll3-antistof
ZA201309174B (en) Polypeptides
IL222301A0 (en) Protease-activatable pore-forming polypeptides
AP3107A (en) 5-Alkynyl-pyrimidines
EP2566479A4 (en) AZA-INDAZOLES
EP2640189A4 (en) 3-deutero-pomalidomide
DK3466977T3 (en) Anti-vla-4-antistoffer
GB201012651D0 (en) Peptides
EP2651505A4 (en) ELECTROPORATION-INDUCED ELECTROSENSIBILIZATION
EP2641891A4 (en) PKC ACTIVATOR-
GB201016494D0 (en) Polypeptide
GB201018480D0 (en) Factors
EP2627674A4 (en) EGFR BASED PEPTIDES
AU4536P (en) TB01 Tibouchina urvilleana
AU4937P (en) FlatinsulGL Myoporum insulare
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
PT2718316T (pt) Polipeptídeos
GB201003906D0 (en) Binding polypeptides
AU2010278V (en) Little Tuffy Lomandra confertifolia
GB201008108D0 (en) Helisuacer III
GB201005840D0 (en) Multi-catch pro